Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Last Updated: January 24, 2022

DrugPatentWatch Database Preview

Details for Patent: 9,034,908

Email this page to a colleague

« Back to Dashboard

Which drugs does patent 9,034,908 protect, and when does it expire?

Patent 9,034,908 protects BENDEKA and is included in one NDA.

This patent has thirty-three patent family members in fifteen countries.

Summary for Patent: 9,034,908

Title:	Formulations of bendamustine
Abstract:	Methods of treatment using bendamustine formulations designed for small volume intravenous administration are disclosed. The methods conveniently allow shorter administration time without the active ingredient coming out of solution as compared to presently available formulations.
Inventor(s):	Sundaram; Srikanth (Somerset, NJ)
Assignee:	EAGLE PHARMACEUTICALS, INC. (Woodcliff Lake, NJ)
Application Number:	13/838,090
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,034,908
Patent Claim Types: see list of patent claims	Use; Composition; Delivery;

Drugs Protected by US Patent 9,034,908

Subscribe to access the full database, or Sign up for a Free Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Eagle Pharms	BENDEKA	bendamustine hydrochloride	SOLUTION;IV (INFUSION)	208194-001	Dec 7, 2015		RX	Yes	Yes	⤷ Sign up for a Free Trial	⤷ Sign up for a Free Trial				FOR USE IN THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA AND/OR NON-HODGKINS LYMPHOMA	⤷ Sign up for a Free Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

International Family Members for US Patent 9,034,908

Subscribe to access the full database, or Sign up for a Free Trial
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Canada	2867295	⤷ Sign up for a Free Trial
Canada	2867343	⤷ Sign up for a Free Trial
China	104271135	⤷ Sign up for a Free Trial
China	104302291	⤷ Sign up for a Free Trial
China	107157988	⤷ Sign up for a Free Trial
Denmark	2827863	⤷ Sign up for a Free Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter

Colorcon

Medtronic

Boehringer Ingelheim

Johnson and Johnson

AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.